Shots:

• Novartis & Target PharmaSolutions collaborates for the onset of global TARGET-DERM study evaluating adult and pediatric patients with immune-mediated inflammatory skin conditions (IMISCs)
• The initial focus of the collaboration is to develop therapies & expand Novartis’ footprints in immune-dermatology for atopic dermatitis (eczema) with further expansion to hidradenitis suppurativa (painful bumps under the skin)- alopecia areata (autoimmune-related hair loss)- and vitiligo (loss of skin pigment)
• TARGET PharmaSolutions has six TARGET studies including TARGET-DERM a global study for (IMISCs) and others for nonalcoholic steatohepatitis (NASH)- hepatocellular carcinoma (HCC)- inflammatory bowel disease (IBD)- primary biliary cholangitis (PBC) and chronic hepatitis B (HBV)  

Click here to read full press release/ article | Ref: Target PharmaSolutions | Image: The Business Journals